Skip to Content
Search Menu

BestPractice Nordic Covers the 2024 ASCO Gastrointestinal Cancers Symposium

BestPractice Nordic is excited to announce the coverage of the 2024 ASCO Gastrointestinal Cancers Symposium.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Relateret indhold

PD-1 Inhibitors Have Shown Remarkable Efficacy

/ BestPractice Nordic
ESMO24Gastrointestinal cancer

Gastrointestinal Cancer: 14 Years to Reach the Final Conclusion

/ BestPractice Nordic
ESMO24Gastrointestinal cancer
Anant Ramaswamy

Adding Docetaxel to FOLFOX/CAPOX in Gastric and Gastroesophageal Adenocarcinomas Does Not Improve Survival

/ Anant Ramaswamy
ASCOGI24Gastrointestinal cancer Play the Video 4:25
Thierry André

Nivolumab plus Ipilimumab – A Potential New Standard-of-Care Treatment Option for Patients with MSI-H/dMMR Advanced Metastatic Colorectal Cancer

/ Thierry André
ASCOGI24Colorectal cancer Play the Video 3:48
Nicole Serapin

The Impact of COVID-19 on the Stage at Presentation for Colorectal Cancer Patients

/ Nicole Serapin
ASCOGI24Colorectal cancer Play the Video 7:11
Kohei Shitara

CheckMate 649’s Four-Year Survival Data on Chemo + Nivolumab for Gastric & Esophageal Cancer

/ Kohei Shitara
ASCOGI24Gastrointestinal cancer Play the Video 02:55

ASCO GI 2024: Targeting HER2 in Gastroesophageal Adenocarcinoma

/ Sofie Pohl
ASCOGI24Breast cancerGastrointestinal cancer
Kohei Shitara

Management of Nausea and Vomiting Following First-Line Zolbetuximab + Chemotherapy

/ Kohei Shitara
ASCOGI24Gastrointestinal cancer Play the Video 03:33
Davi Said Gonçalves Celso

Meta Analysis of Three Trials: FAST, SPOTLIGHT & GLOW Exploring the New Target Claudin 18.2 in Gastric Cancer

/ Davi Said Gonçalves Celso
ASCOGI24Gastrointestinal cancer Play the Video 2:51
Back to top